Two New Post-Hoc Analyses of TRA 2°P TIMI 50 Study Showed ZONTIVITY® (vorapaxar) Added to Aspirin and/or Clopidogrel Reduced Acute Limb Ischemia and Peripheral Revascularizations, Respectively, in Certain Patients with Peripheral Arterial Disease

Dateline City: KENILWORTH, N.J. These and other post-hoc subgroup analyses from TRA-2°P are being presented at the 2015 American College of Cardiology Scientific Sessions KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from two post-hoc analyses of the TRA 2°P TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) trial of ZONTIVITY® (vorapaxar), one of the largest secondary prevention studies of an antiplatelet medicine. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news